Compare ICCM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICCM | IFRX |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | Israel | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 60.6M |
| IPO Year | 2013 | 2017 |
| Metric | ICCM | IFRX |
|---|---|---|
| Price | $0.61 | $0.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $8.50 |
| AVG Volume (30 Days) | 169.8K | ★ 274.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $31.38 | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.71 |
| 52 Week High | $1.53 | $1.94 |
| Indicator | ICCM | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 46.47 |
| Support Level | $0.59 | $0.81 |
| Resistance Level | $0.74 | $0.91 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 78.41 | 54.63 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.